A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

Last updated:
2026-07-18
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A PHASE 2B RANDOMIZED, DOUBLE-BLIND, ACTIVE-AND PLACEBOCONTROLLED, PARALLEL-GROUP, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INDUCTION AND MAINTENANCE COMBINATION THERAPY WITH GUSELKUMAB AND GOLIMUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Intervention/treatment:
TREMFYA (GUSELKUMAB) / SIMPONI (GOLIMUMAB)
Medical condition:
ULCERATIVE COLITIS
Protocol code:
78934804UCO2001
Control number:
265967
Status:
Active, not recruiting
Approved:
August 10, 2022
Trial phase:
Phase 2
For more information:
ClinicalTrials.gov - NCT05242484
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years to 65 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Sponsor
JANSSEN RESEARCH AND DEVELOPMENT LLC

Locations

Hopital Chicoutimi
Saguenay, G7H3C3
Viable Clinical Research
Bridgewater, B4V 3N2

Alberta

Covenant Health/Grey Nuns hospital
Edmonton, Alberta, T6L 6K3
Foothills Hospital
Calgary, Alberta, T2N 2T9
Gastroenterology and Internal Medicine Research Institute (GIRI)
Edmonton, Alberta, T5R 1W2

British Columbia

Columbia Gastroenterology
New Westminster, British Columbia, B2W 6L4
GIRI Gastrointestinal Research Institute
Vancouver, British Columbia, V6Z 2K5
PerCuro Clinical Research Ltd.
Victoria, British Columbia, V8P 2P5
The Gordon & Leslie Diamond Health Care Center
Vancouver, British Columbia, V5Z 1M9
The Medical Arts Health Research Group
Vancouver, British Columbia, V7M 2H4

Manitoba

Health Sciences Centre
Winnipeg, Manitoba, R3A 1R9

Nova Scotia

Nova Scotia Health Authority
Halifax, Nova Scotia, B3H 1V7
Viable Clinical Research 1
Dartmouth, Nova Scotia, B2W 6L4

Ontario

London Health Sciences Centre - University Campus
London, Ontario, N6A 5A5
Toronto Immune and Digestive Health Institute Inc
Toronto, Ontario, M6A 3B4

Quebec

CIUSSS de l Est de l Ile de Montreal Installation Hopital Maisonneuve Rosemont
Montreal, Quebec, H1T 2M4
CMIIM, Centre médical L'Enjeu
Mount Royal, Quebec, H3P 3E5
McGill University - Health Centre - Montreal General Hospital
Montreal, Quebec, H3G 1A4
St. Jerome Medical Research
Saint-Jérôme, Quebec, V8R 4R2
Did you find what you were looking for?